Proactive Investors - Run By Investors For Investors

Renovo ends Prevascar development

Renovo ends Prevascar development

Renovo (LON:RNVO) today confirmed that it will now perform any further work on Prevascar following the completion of a clinical trial.

The company says that it will continue to focus on its merger and acquisition plans and its share buy-back programme as a way to enhance shareholder value.

The clinical trial results follow the disappointing results of the Juvista trial in February 2011. Subsequently, Renovo’s remaining trials which had already been contracted had continued.

Today, Renovo reported that 56 patients were enrolled in the trial of the Prevascar scar treatment. It said there was a ‘small but significant’ reduction in scar width compared to placebo after one month, however by month 12 there was in fact a ‘small but significant’ improvement in the placebo scar width compared to Prevascar. 

Meanwhile, most other assessments showed no difference between treatments. 

In November, Renove told investors that it was considering all options to maximise value including acquisitions and mergers of external companies.


Register here to be notified of future RNVO Company articles


December 13 2012
December 15 2011
November 18 2011

Related Articles

May 11

A significant landmark was passed with little fanfare or market reaction recently that could have a significant bearing on Tissue Regenix's commercial success.

June 19
Collagen Solutions has set itself the goal of becoming a £100mln company in the next five years.
October 16 2014

Nanobiotix said it has received approval from French regulators to embark on phase II/III registration of its lead product.

© Proactive Investors 2015